EQS-News: Formycon AG / Key word: Regulatory Admission/Miscellaneous
Formycon announces File Acceptance for FYB203, a biosimilar candidate to Eylea®1 , by the U.S..
EQS-News: Formycon AG / Key word(s): Regulatory Admission/MiscellaneousFormycon announces File Acceptance for FYB203, a biosimilar candidate to Eylea®1 (aflibercept), by the U.S. Food and Drug Administration (FDA) 29.08.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Press.
EQS-News: Formycon announces submission of the biologics license application (BLA) for FYB203, an aflibercept biosimilar candidate to the U.S. Food and Drug Administration (FDA) finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.